This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy
Great leaders exercise emotional intelligence, and they are very adept at understanding their strengths and weaknesses as well as those around them and can assess a situation pretty accurately and in a timely fashion. In other words, they are intuitive. And though they listen to the advice given by others, they make their own decisions and do not hesitate to stand for what is right.
M. Fabiana Lacerca-Allen has over 30 years of experience in legal and compliance roles, working for leading American companies such as Aimmune, Elan, Mylan, Bristol-Myers Squibb Company, Microsoft, Merck, and AT&T. She has counseled and litigated in the field of international business transactions and international environmental law. She has extensive experience in the pharmaceutical industry in leadership roles in charge of legal and compliance teams. She has counseled and represented clients on a broad range of questions, including strategic business initiatives ensuring compliance with laws and regulations, and corporate policy. Ms. Lacerca-Allen has provided legal support and strategic advice on opportunities and trends in law particularly within the government sector, as well as with major and strategic corporate accounts. Fabiana has established policies and oversight on key areas of compliance affecting international markets, and she has been able to positively impact the perception of compliance, creating compliance training programs and relevant standard operating procedures and has been involved in validating and aiding due diligence in the compliance industry, frequently being requested as speaker and participant in forums. She has been recognized in the industry by Hispanic Executive Magazine in 2013, http://hispanicexecutive.com/2013/fabiana-lacerca-allen/; recognized as 2015 Women in Leadership, Inspiring Leaders: http://www.theguardian.com/women-in-leadership/2015/may/12/know-who-you-want-to be-kidnapped-with-and-four-more-tips-for-leaders; served as Chair to the Bay Area Ethics & Compliance Association (BECA); and served as Co Chair for CBI, an Advanstar company serving the Life Sciences industry. Ms. Lacerca-Allen was invited to join the Gioja Research Institute while she was a student researching on environmental law. She was recipient of 1992 UCLA’s tuition waiver based on merit and recognition, and she represented UCLA in the Roscoe Foundation National Essay Contest submitting a paper on Global Warming. About your organization Aimmune was created in response to a united call to action from the leading minds and key stakeholders in food allergy who met at an advocacy-sponsored research retreat in 2011 to reach consensus on the direction of food allergy treatment research. Among the outcomes of the retreat, the group concluded that a standard oral immunotherapy (OIT) approach needed to be established, and associated products needed to be developed. When no pharmaceutical company showed interest in developing an OIT treatment, the food allergy community formed Aimmune. Today, Aimmune is working to fulfill the 2011 shared vision of developing a peanut allergy treatment and making it available to allergists for patients worldwide.
Brenda Crabtree is the Director, Compliance Auditing and Monitoring at Aimmune Therapeutics. Prior to this, Brenda worked as an intellectual property attorney for biotechnology and pharmaceutical companies and advised pharmaceutical and medical device companies on various compliance matters including corporate policy and strategy, privacy, transparency, and fair market value. Brenda is a humanitarian who began her career in public service as a U.S. Naval Officer, and she applies her strong sense of “doing the right thing” to her work as a compliance professional.
Laura Hamm is the Senior Compliance Director at Aimmune Therapeutics. Before joining Aimmune, Laura was the Compliance Officer of medical device manufacturer Stryker’s Neurovascular division, a nearly $1B business, and Stryker’s only global division. At Stryker, Laura oversaw all elements of Neurovascular’s compliance program. As a global Compliance Officer, Laura has witnessed the evolution of international regulations, and recognizes the importance of cross-border collaboration to meet global business goals. Laura is passionate about integrating compliance into business DNA, and empowering business partners to achieve objectives with high integrity. Prior to industry, Laura was an educator in the California public school system, focusing on literacy in low-income communities.
Lisa brings over 15 years of Executive Assistant experience and has been instrumental in the following areas: Strategic Business Planning, Communications, Project Management, Operations, and Human Resources. Lisa holds a Bachelor of Science in Organizational Behavior and Leadership from the University of San Francisco and a Master of Science in Business Administration with a focus in Human Resource Management.
Aimmune was created in response to a united call to action from the leading minds and key stakeholders in food allergy who met at an advocacy-sponsored research retreat in 2011 to reach consensus on the direction of food allergy treatment research. Among the outcomes of the retreat, the group concluded that a standard oral immunotherapy (OIT) approach needed to be established, and associated products needed to be developed. When no pharmaceutical company showed interest in developing an OIT treatment, the food allergy community formed Aimmune. Today, Aimmune is working to fulfill the 2011 shared vision of developing a peanut allergy treatment and making it available to allergists for patients worldwide. Aimmune is on a mission to transform the lives of patients and their families by developing pharmaceutical therapies to prevent, manage, and treat food, GI, and metabolic-related diseases.
Aimmune was created in response to a united call to action from the leading minds and key stakeholders in food allergy who met at an advocacy-sponsored research retreat in 2011 to reach consensus on the direction of food allergy treatment research. Among the outcomes of the retreat, the group concluded that a standard oral immunotherapy (OIT) approach needed to be established, and associated products needed to be developed. When no pharmaceutical company showed interest in developing an OIT treatment, the food allergy community formed Aimmune. Today, Aimmune is working to fulfill the 2011 shared vision of developing a peanut allergy treatment and making it available to allergists for patients worldwide. Aimmune is on a mission to transform the lives of patients and their families by developing pharmaceutical therapies to prevent, manage, and treat food, GI, and metabolic-related diseases.
Aimmune was created in response to a united call to action from the leading minds and key stakeholders in food allergy who met at an advocacy-sponsored research retreat in 2011 to reach consensus on the direction of food allergy treatment research. Among the outcomes of the retreat, the group concluded that a standard oral immunotherapy (OIT) approach needed to be established, and associated products needed to be developed. When no pharmaceutical company showed interest in developing an OIT treatment, the food allergy community formed Aimmune. Today, Aimmune is working to fulfill the 2011 shared vision of developing a peanut allergy treatment and making it available to allergists for patients worldwide. Aimmune is on a mission to transform the lives of patients and their families by developing pharmaceutical therapies to prevent, manage, and treat food, GI, and metabolic-related diseases.
Aimmune was created in response to a united call to action from the leading minds and key stakeholders in food allergy who met at an advocacy-sponsored research retreat in 2011 to reach consensus on the direction of food allergy treatment research. Among the outcomes of the retreat, the group concluded that a standard oral immunotherapy (OIT) approach needed to be established, and associated products needed to be developed. When no pharmaceutical company showed interest in developing an OIT treatment, the food allergy community formed Aimmune. Today, Aimmune is working to fulfill the 2011 shared vision of developing a peanut allergy treatment and making it available to allergists for patients worldwide.
